Merck receives EU nod for first subcutaneous formulation, promising faster cancer treatment
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
These initiatives will harness top scientific talent and advanced AI technologies to develop new ways to slow the rise of drug-resistant infections
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
The formulation is backed by over 80 clinical trials and 200 scientific publications
The licence covers Actimed’s existing patents, its proprietary know-how and any future related patents, giving Mankind full control to advance the products under its own brands
The 2025 edition of the EdelGive Hurun list recognizes 24 exceptional women leaders for their philanthropic impact across critical areas
SOMA Color Mind is designed to simplify and accelerate color setup directly on the printing press
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
Over 700 exhibitors from APAC, Europe, the US, and beyond showcased the latest in personal care innovation
Subscribe To Our Newsletter & Stay Updated